Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Dec 18, 2025; 15(4): 108413
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.108413
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.108413
Dietary interventions vs octreotide for post liver transplantation chylous ascites: A scoping review
Eyad Gadour, Hadi Kuriry, Mohammed S AlQahtani, Multiorgan Transplant Centre of Excellence, Liver Transplantation Unit, King Fahad Specialist Hospital, Dammam 32253, Saudi Arabia
Eyad Gadour, Department of Medicine, Faculty of Medicine, Zamzam University College, Khartoum 11113, Sudan
Bogdan Miutescu, Department of Gastroenterology and Hepatology, Victor Babes University of Medicine and Pharmacy, Timisoara 300041, Romania
Bogdan Miutescu, Advanced Regional Research Centre for Gastroenterology and Hepatology, Victor Babes University of Medicine and Pharmacy, Timisoara 300041, Romania
Zeinab Hassan, Department of Internal Medicine, Stockport Hospitals NHS Foundation Trust, Manchester SK2 7JE, United Kingdom
Khalid Jebril Shrwani, Department of Medical Virology, Public Health Authority, Southern Sector, Jazan 45142, Saudi Arabia
Ehab Abufarhaneh, Liver and Small Bowel Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia
Ehsaneh Taheri, Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran 14117-13135, Iran
Mohammed S AlQahtani, Department of Surgery, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia
Author contributions: Gadour E, Miutescu B, Shrwani KJ, Hassan Z, Taheri E, Abufarhaneh E and Kuriry H contributed to the conceptualization; AlQahtani MS, Taheri E, Miutescu B, Kuriry H, Hassan Z, Abufarhaneh E and Gadour E contributed to resources, writing, reviewing, and editing; Gadour E and AlQahtani MS were responsible for supervision and project administration, respectively; all authors contributed to and approved the final draft of the manuscript; Gadour E was responsible for the overall content.
Conflict-of-interest statement: The authors declare no conflicts of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bogdan Miutescu, MD, PhD, Assistant Professor, Consultant, Department of Gastroenterology and Hepatology, Victor Babes University of Medicine and Pharmacy, Victor Babes, Timisoara 300041, Romania. bmiutescu@yahoo.com
Received: April 14, 2025
Revised: May 17, 2025
Accepted: August 13, 2025
Published online: December 18, 2025
Processing time: 219 Days and 22.2 Hours
Revised: May 17, 2025
Accepted: August 13, 2025
Published online: December 18, 2025
Processing time: 219 Days and 22.2 Hours
Core Tip
Core Tip: Chylous ascites (CA) is a rare complication after liver transplantation, occurring in 0.6% to 4.7% of cases. This review of 13 studies highlighted the effectiveness of interventions for CA management. Low-fat diet with medium-chain triglyceride supplementation, used as first-line therapy in most studies, showed resolution rates of 62.5% to 100%. Octreotide, primarily used as second-line therapy, demonstrated resolution rates of 83.3% to 100%. Combination therapy was significantly more effective than dietary management alone (97.8% vs 78.9%; P = 0.02). A stepwise approach is recommended, starting with dietary interventions, and progressing to octreotide when necessary. However, further research is needed to optimize CA management after liver transplantation.